Table E 23 Summary of treatment breakdown for high grade abnormalities (CIN 2 or CIN 3) - cohort offered vaccination at age 12 years Test technology Difference in high grade - - Percentage of % change in ASR§ mortality squamous abnormalities* high-grade compared to CP (range‡)†† (CIN2 or CIN3) detected treatments that are compared to CP†† for CIN2* (range‡) - Difference in overall Difference in CIN 2 Difference in CIN 3 Difference in overall cases of cases of CIN 2 or CIN 3 cases cases CIN 2 or CIN 3 (range‡) (range‡) (range‡) (range‡) Current Practice - - - 44% - Conventional cytology (-2346, -1300) (-1833, -1049) (-513, -251) (34%, 39%) (8%, 19%) Manually-read LBC (-2482, -470) (-2398, -927) (-84, 457) (27%, 37%) (-12%, 6%) Image-read LBC (-2080, -1) (-2005, -419) (-74, 418) (31%, 40%) (-14%, 4%) Primary HPV screening with cytology triage (-1761, -107) (-1941, -603) (173, 532) (30%, 39%) (-16%, -8%) Primary HPV screening with partial genotyping (-1711, -116) (-1892, -597) (175, 508) (31%, 39%) (-16%, -11%) primary HPV and adjunctive cytology co-testing (-1586, 86) (-1792, -423) (199, 546) (32%, 40%) (-17%, -10%) CP – current practice * Using female Australian population as predicted for 2015 § Age-standardised (0-84 years) using 2001 Australian population as the standard population ‡ Minimum and maximum values across all strategies within each test technology were used as the range †† Negative values represent a decrease
Table E 23 Summary of treatment breakdown for high grade abnormalities (CIN 2 or CIN 3) - cohort offered vaccination at age 12 years Test technology Difference in high grade squamous abnormalities* (CIN2 or CIN3) detected compared to CP†† - - Percentage of high-grade treatments that are for CIN2* (range‡) % change in ASR§ mortality compared to CP (range‡)†† - Difference in overall cases of CIN 2 or CIN 3 (range‡) Difference in CIN 2 cases (range‡) Difference in CIN 3 cases (range‡) Difference in overall cases of CIN 2 or CIN 3 (range‡) Current Practice - - - 44% - Conventional cytology (-2346, -1300) (-1833, -1049) (-513, -251) (34%, 39%) (8%, 19%) Manually-read LBC (-2482, -470) (-2398, -927) (-84, 457) (27%, 37%) (-12%, 6%) Image-read LBC (-2080, -1) (-2005, -419) (-74, 418) (31%, 40%) (-14%, 4%) Primary HPV screening with cytology triage (-1761, -107) (-1941, -603) (173, 532) (30%, 39%) (-16%, -8%) Primary HPV screening with partial genotyping (-1711, -116) (-1892, -597) (175, 508) (31%, 39%) (-16%, -11%) primary HPV and adjunctive cytology co-testing (-1586, 86) (-1792, -423) (199, 546) (32%, 40%) (-17%, -10%) CP – current practice * Using female Australian population as predicted for 2015 § Age-standardised (0-84 years) using 2001 Australian population as the standard population ‡ Minimum and maximum values across all strategies within each test technology were used as the range †† Negative values represent a decrease
Executive%20Summary%20notated%2013.6.14.docx